Octreotide Acetate
Octreotide Acetate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Octreotide Acetate; Generic name: OCTREOTIDE ACETATE; Manufacturer: Meitheal Pharmaceuticals, Inc..
| Brand name | Octreotide Acetate |
|---|---|
| Generic name | OCTREOTIDE ACETATE |
| Manufacturer | Meitheal Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associa |
| Dosage | 2 DOSAGE AND ADMINISTRATION Octreotide Acetate injection may be administered subcutaneously or intravenously. ( 2.1 ) Acromegaly : Recommended initial Octreotide Acetate injection dosage is 50 mcg three times daily during the initial 2 weeks of therapy. Maintenance dose 100 mcg to 500 mcg three times daily. ( 2.2 ) Carcinoid Tumors : Recommended dosage range of 100 mcg to 600 mcg daily in two to four divided doses during the initial 2 weeks of therapy. ( 2.3 ) VIPomas : Recommended dosage range |
| Active ingredient(s) | OCTREOTIDE ACETATE |
| Route | INTRAVENOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01962c67-e551-47b6-a276-e1ae1860d2a4 |